Valeant Falls Into Tailspin off Real Money Report

At this point you would be better off riding aboard the Titanic than holding Valeant Pharmaceuticals stock, at least according to short seller Andrew Left. Left, who was first to put a spotlight Valeant's accounting improprieties last fall, is once again going short on the Canadian drugmaker, Left said in a phone interview with Real Money. 'I think its obvious its a zero now,' Left said, emphasizing that Sequoia's decision to sell its remaining stake in Valeant on Tuesday is a clear indicator there are more problems at Valeant. 'The fact that they're selling tells everything' Left added, sending Valeant shares into a tailspin following the publication of his position.

Employees of TheStreet are restricted from owning individual securities.